Lead Optimization. The term “
Lead Optimization. (a) Telik shall diligently undertake a maximum of [*] Lead Optimization Projects (as defined below) concurrent for Sanwa at any given time, each with respect to a Family of Compounds (as defined below) as Sanwa shall select by providing written notice to Telik. For a period of [*] commencing on [*], Telik shall undertake, [*], a Lead Optimization Project for the [*] Family of Compounds. If Telik completes such Lead Optimization Project in less than [*], or if Sanwa notifies Telik that it wishes to substitute another Lead Optimization Project in place of a previously selected Lead Optimization Project, Telik shall undertake such new or substitute Lead Optimization Project as Sanwa may select, taking into account the scientific advice of the "RMC," as such term is defined in the Collaboration Agreement between Telik and Sanwa dated December 20, 1996, as amended ("Collaboration Agreement"), by providing written notice to Telik, until the expiration of the above [*] period [*]. Telik shall also diligently undertake concurrent with the Lead Optimization Project for the [*] Family of Compounds a [*] Lead Optimization Project as selected by Sanwa including, for example, a Lead Optimization Project for the [*] Family of Compounds. If Sanwa requests that Telik undertake a [*] Lead Optimization Project at any time during the [*] period described above, or continue a Lead Optimization Project after the expiration of the [*] period described above, both after taking into account the scientific advice of the RMC, Sanwa shall pay Telik [*], working through the RMC.
Lead Optimization. Pfizer shall propose to ArQule at least one (1) lead optimization program, the subject matter of which shall *, on which it will collaborate with ArQule during the Agreement Period. The Parties shall negotiate in good faith the terms and conditions of such lead optimization program in a separate agreement.
Lead Optimization. The Research Committee will update the Research Plan to provide for the accelerated lead optimization of the selected Committed Compound Sets with Committed Targets in the Collaboration, subject to Steering Committee approval. The Research Plan will set project priorities and define success criteria for a GLP Toxicology Candidate. As described in the Collaboration Plan, in a typical project the parties will iteratively develop and test Analog Compounds based on Committed Compounds. The parties will determine whether a proposed Analog Compound is an Available Compound before synthesis, and only Available Compounds will proceed to synthesis and testing in the Collaboration. The Analog Compounds developed by the parties shall automatically become Committed Compounds under this Agreement and, therefore, the Committed Compound Set for the Committed Target will likely expand as a result of the lead optimization efforts. At the discretion of the Research Committee, the parties may also use such Analog Compounds in primary screens against other ACADIA Targets. The parties anticipate that lead optimization of Committed Compounds will occur in two stages:
Lead Optimization. 00.Xxxxxxx shall, concurrent with sending the Company Selection Notice, make the payment(s) to Cengent as indicated in Paragraph above. Also, Company shall pay $150,000 to Cengent upon selecting by Company of a Lead Optimization Compound or a derivative (e.g., homologs, analogs, polymorphs, isomers, prodrugs and formulations of the Lead Optimization Compound), payable as a number of shares of Company stock based on the most recent stock price accepted by an independent investor in an arm's length transaction.
Lead Optimization. Upon designation of at least one Lead Compound for a given Target, the Parties will determine which Party shall primarily conduct Lead Optimization. The selected Party, in consultation with the other Party, shall conduct a Lead Optimization program consisting of medicinal chemistry synthesis of analogs of the Lead Compound(s) and testing of these analogs in a series of assays to determine efficacy, selectivity and pharmaceutical properties, as set forth in the Research Plan. Additional pharmacological studies of analogs may also be performed by the selected Party, as set forth in the Research Plan. The JRC shall review the results of the assays, determine which Lead Compound(s) should be designated as IND Candidates, and submit its recommendations to the JMC for written approval. No more than [*] days after the JRC’s recommendation is presented to the JMC, the JMC shall determine in writing under Section 2.3(c)(ii) whether such Lead Compound(s) merit designation as IND Candidates. After the [*] day period following the end of the Collaboration Term, if CVT does not take an exclusive license to Collaboration Compounds which are Active against a particular Target pursuant to Section 4.6, then such Collaboration Compounds shall be deemed Non-Collaboration Compounds, and PTC shall have the right to screen such Non-Collaboration Compounds and to develop and commercialize products incorporating such Non-Collaboration Compounds with no royalty or milestone obligations to CVT for such products under this Agreement. If, prior to the [*] day following the end of the Collaboration Term, CVT exercises its right to obtain an exclusive license pursuant to Section 4.6 to Collaboration Compounds identified as Active against such Target in the applicable Lead Optimization program (as documented by the JMC pursuant to Section 2.3(c)(iii)), then such Collaboration Compounds shall be subject to CVT’s license pursuant to Section 4.6 for so long as such license remains in effect. [*] Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Lead Optimization. As used herein "Lead Optimization" shall mean design and/or synthesis of new chemical entities based on a Lead Compound using Centaur's SAR program or other technologies for drug discovery and drug design in order to find compounds meeting CD Nomination Criteria.
Lead Optimization. The Research Committee will update the Research Plan to provide for the accelerated lead optimization of qualified Collaboration Compound Sets or Collaboration Compounds and the corresponding Collaboration Targets (or, if the GTC Target is unknown, the anti-infective activity identified in the relevant assay), subject to Steering Committee approval. The Research Plan will set project priorities and define success criteria for a GLP Toxicology Candidate. As described in the Collaboration Plan, in a typical project the Parties will iteratively develop and test Analog Compounds based on Collaboration Compounds. The Parties will determine whether a proposed Analog Compound is an Available Compound before synthesis, and only Available Compounds will proceed to synthesis and testing in the Collaboration. Analog Compounds developed by the Parties shall automatically become Collaboration Compounds and, therefore, the Collaboration Compound Set for the Collaboration Target will likely expand as a result of the lead optimization efforts. At the discretion of the Research Committee, the Parties may also use such Analog Compounds in primary screens against other GTC Targets or assays, as described in Section 3.4. The Research Committee may release from the scope of the Collaboration any Collaboration Compounds, Collaboration Compound Sets, and Collaboration Targets that are no longer of interest to the Collaboration, subject to Steering Committee approval; provided, however that the same shall continue to be subject to the rights of the Parties as set forth in Section 9.5. below. Lead optimization activities will continue in a project until the Research Committee recommends that further efforts be stopped and the Steering Committee accepts such recommendation. The Parties anticipate that lead optimization activities will continue in a project until the Parties (i) develop an acceptable GLP Toxicology Candidate, (ii) determine that they are unlikely to develop an acceptable GLP Toxicology Candidate and cease development activities with respect thereto, or (iii) decide to seek commercialization of the Collaboration Work Product as described in Section 3.9 herein.
Lead Optimization. During the Collaborative Research Term, the JRDC shall review and prioritize each Lead Compound on a regular basis, allocating the split of responsibilities and resources between the Parties with the goal of advancing a prioritized Lead Compound to Development Candidate by the conduct of the Lead Optimization Responsibilities set forth in the Research Plan, and the factors described below. In general, the responsibilities for [ * ] of a Lead Compound and associated [ * ] (including [ * ] and [ * ]) shall remain with [ * ] that [ * ] such [ * ]; provided, however, that the Parties may agree to allocate some activities (and transfer Lead Compounds) to [ * ] that [ * ] such [ * ] if [ * ] has [ * ] and [ * ] that are [ * ] to the [ * ] (e.g., in the areas of specific [ * ] or [ * ] models, [ * ] assets or access to [ * ])]. During the Collaborative Research Term, each Party shall [ * ] to [ * ] the [ * ] that are [ * ] to [ * ] by [ * ] and to update the JRDC with the progress and results of such conduct. The JRDC shall assess the status of the Lead Compounds, and, if a Lead Compound meets the Development Candidate Nomination Criteria, or if the JRDC otherwise determines that a Lead Compound should be advanced as a Development Candidate for preclinical development, then the JRDC shall nominate such Lead Compound as a Development Candidate to [ * ]. [ * ] shall promptly (and in good faith) review such nomination and determine whether such Lead Compound shall be advanced for preclinical development by becoming a Development Candidate. If [ * ] determines to approve such Lead Compound as a Development Candidate, then [ * ] shall promptly notify the JRDC, and such Lead Compound shall be deemed to be a Development Candidate and shall no longer be deemed to be a Lead Compound. [ * ] shall also determine which Party would be responsible for CMC Activities, preclinical development, IND submission and conduct of the first Phase I Clinical Trial for such Development Candidate. If the JRDC decides not to nominate a Lead Compound as a Development Candidate, or if [ * ] does not approve a Lead Compound as a Development Candidate, and the JRDC [ * ] recommends additional work to be performed on such Lead Compound, then, [ * ] that [ * ] such [ * ] shall use Diligent Efforts to conduct such additional work and re-submit such Lead Compound to the JRDC; provided, however, that the JRDC shall have the sole discretion to prioritize such additional work relative to any work bein...
Lead Optimization. The third stage of the Discovery Optimization Program will progress one of the Targets through lead optimization to identify qualified Active Compounds [*****]. During this stage of the program, [*****] of Derivative Compound synthesis and optimization will be executed[*****].
